{"product_id":"jxr-fertility-swot-analysis","title":"Jinxin Fertility SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Strategic Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eJinxin Fertility shows strong market positioning in China’s growing reproductive health sector, supported by specialized clinics and service diversification, yet faces regulatory sensitivity and competitive pressure that could constrain margins; our full SWOT unpacks these dynamics and strategic levers. Purchase the complete SWOT analysis for a professionally formatted, editable Word and Excel package with research-backed insights to inform investment, planning, or M\u0026amp;A decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDominant Market Leadership Across Dual Jurisdictions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs of late 2025, Jinxin Fertility is the largest private assisted reproductive services provider in China and a leading U.S. West Coast operator via HRC Fertility, treating over 120,000 cycles cumulatively and generating roughly RMB 6.8 billion (≈USD 950 million) annualized revenue in 2024–25; this scale boosts brand recognition across divergent regulatory regimes. The dual-market footprint captures cross-border patient flows—about 8–12% of patients in 2024 came from abroad—while established reputation and scale raise entry costs for new competitors in the specialized fertility sector.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSuperior Clinical Success Rates and Medical Expertise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eJinxin Fertility posts IVF success rates well above national norms—Chengdu and Shenzhen clinics report 57.5% versus China’s typical 30–40%—driving higher patient volume and repeat visits.\u003c\/p\u003e\n\u003cp\u003eMedical strength rests on 300+ physicians and adoption of third‑generation IVF tech (PGT, time‑lapse incubators, ICSI), supporting clinical outcomes and premium pricing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComprehensive Full-Cycle Service Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eJinxin Fertility moved from pure-play IVF to a full-cycle reproductive platform, adding genetic screening, prenatal exams, postpartum care and anti-aging clinics, boosting patient LTV and cutting churn; in 2024 integrated-service patients rose ~38% year-over-year and non-IVF revenue reached ~28% of total revenue in FY2024. This holistic model answers demand for seamless care and diversifies revenue across lifecycle touchpoints.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Operational Efficiency and High-Margin Profile\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDespite macro headwinds, Jinxin Fertility preserves strong operations with gross margins above 50% historically and a lean management model that keeps unit costs low.\u003c\/p\u003e\n\u003cp\u003eNet cash from operations hit 1.2 billion yuan in H1 2024, giving the firm liquidity for tech upgrades and clinic reinvestment without heavy external funding.\u003c\/p\u003e\n\u003cp\u003eThis cash-plus-margin profile supports competitive advantage in a capital‑intensive fertility market that demands continual equipment and R\u0026amp;D spend.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGross margin: \u0026gt;50% (historical)\u003c\/li\u003e\n\u003cli\u003eOperating cash: 1.2 bn CNY (H1 2024)\u003c\/li\u003e\n\u003cli\u003eLow operating leverage via efficient management\u003c\/li\u003e\n\u003cli\u003eFunds available for capex and tech upgrades\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Geographic Clusters and Referral Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eJinxin Fertility clusters 32 clinics and hospitals in high-demand regions like the Greater Bay Area and Sichuan, leveraging a 50+ hospital referral network to feed patient volume and smooth capacity use.\u003c\/p\u003e\n\u003cp\u003eThe hub-and-spoke model cuts per-patient fixed costs, boosts negotiating power with suppliers, and focuses marketing on urban professionals where average ARPU is higher; FY2024 revenue per clinic weighted toward these clusters by ~18%.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e32 clinics\/hospitals\u003c\/li\u003e\n\u003cli\u003e50+ referring hospitals\u003c\/li\u003e\n\u003cli\u003eHigher ARPU in key clusters (+18% FY2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarket Leader: RMB6.8bn Revenue, 120k Cycles, 57.5% Top IVF Success\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMarket leader in China and US West Coast (HRC), ~120,000 cumulative cycles, ~RMB 6.8bn revenue (2024–25), \u0026gt;50% gross margin, 1.2bn CNY operating cash H1 2024; 32 clinics, 50+ referring hospitals, 57.5% top clinic IVF success vs 30–40% national, non‑IVF revenue ~28% FY2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCumulative cycles\u003c\/td\u003e\n\u003ctd\u003e~120,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue (2024–25)\u003c\/td\u003e\n\u003ctd\u003eRMB 6.8bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating cash H1 2024\u003c\/td\u003e\n\u003ctd\u003e1.2bn CNY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinics \/ referrals\u003c\/td\u003e\n\u003ctd\u003e32 \/ 50+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop clinic IVF rate\u003c\/td\u003e\n\u003ctd\u003e57.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNon‑IVF revenue\u003c\/td\u003e\n\u003ctd\u003e~28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT overview of Jinxin Fertility, highlighting its core strengths and operational weaknesses, while mapping key market opportunities and external threats shaping the company’s strategic outlook.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT matrix tailored to Jinxin Fertility for rapid strategic alignment and stakeholder-ready summaries.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSubstantial Financial Losses from Impairment Charges\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn H1 2025 Jinxin Fertility posted a net loss of about 1.04 billion yuan, reversing prior profits; this was driven mainly by roughly 730–820 million yuan in impairment charges on intangible assets and goodwill tied to U.S. and Laos operations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeographic Concentration and Regional Revenue Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpa significant portion of jinxin revenue is concentrated in regions like chengdu making the group vulnerable to local economic shifts and policy changes.\u003e\n\u003cpchengdu operations reported a drop in ivf cycles h1 after patient visit process changes directly squeezing service volumes and revenue.\u003e\n\u003cpthis limited geographic diversification within china means local disruptions can disproportionately harm groupwide financials raising volatility and execution risk.\u003e\n\u003c\/pthis\u003e\u003c\/pchengdu\u003e\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnderperformance of International Business Units\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eJinxin Fertility’s U.S. and Laos expansions have lagged, triggering impairment charges of RMB 320 million in FY2024 and dragging group revenue growth to 3.8% in 2024 vs. 18% domestically; the U.S. business faces a different regulatory and insurance landscape that raises operating costs and lowers margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Dependency on Urban Professional Demographics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eJinxin’s revenue is concentrated in high-income urban professionals—about 65% of Chinese sales come from households earning over 800,000 yuan annually—making demand sensitive to upper‑middle class spending shifts.\u003c\/p\u003e\n\u003cp\u003eWith China GDP growth slowing to ~4.5% in 2024 and IVF costs often paid out‑of‑pocket (average cycle ~80,000–120,000 yuan), economic shocks can push patients to delay or skip treatment, hurting volumes.\u003c\/p\u003e\n\u003cp\u003eWhat this hides: regional rural markets and lower‑income segments remain underpenetrated, limiting countercyclical buffers and diversification.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e65% revenue from \u0026gt;800k yuan households\u003c\/li\u003e\n\u003cli\u003e2024 China GDP ~4.5%\u003c\/li\u003e\n\u003cli\u003eAverage IVF cycle 80k–120k yuan out‑of‑pocket\u003c\/li\u003e\n\u003cli\u003eLow rural penetration limits downside protection\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManagement Instability and Leadership Transitions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe sudden mid-2025 departure of Jinxin Fertility’s CFO, with the CEO acting as interim CFO, has intensified corporate governance concerns amid a 28% year-over-year revenue decline in H1 2025 and RMB 420 million net loss, weakening investor trust.\u003c\/p\u003e\n\u003cp\u003eHigh-level turnover during financial distress can slow strategic choices, raise refinancing costs, and complicate compliance in a tightly regulated assisted reproductive services market.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCFO exit: mid-2025\u003c\/li\u003e\n\u003cli\u003eCEO serving as acting CFO\u003c\/li\u003e\n\u003cli\u003eH1 2025 revenue down 28% YoY\u003c\/li\u003e\n\u003cli\u003eH1 2025 net loss RMB 420 million\u003c\/li\u003e\n\u003cli\u003eLeadership continuity critical for regulatory navigation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eChengdu concentration, costly IVF and impairments drive 28% revenue drop, RMB420m loss\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eConcentrated China footprint (Chengdu) and high‑income customer mix (65% \u0026gt;800k yuan) raise demand sensitivity; H1 2025 shows 28% revenue decline and RMB 420m loss. Impairments (~RMB 730–820m in H1 2025; RMB 320m in FY2024) from U.S.\/Laos ops cut profitability; average IVF cost 80k–120k yuan out‑of‑pocket limits volume resilience. CFO exit (mid‑2025) heightens governance risk.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eH1 2025 rev change\u003c\/td\u003e\n\u003ctd\u003e-28% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eH1 2025 net loss\u003c\/td\u003e\n\u003ctd\u003eRMB 420m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImpairments H1 2025\u003c\/td\u003e\n\u003ctd\u003eRMB 730–820m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2024 impairment\u003c\/td\u003e\n\u003ctd\u003eRMB 320m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCustomer \u0026gt;800k\u003c\/td\u003e\n\u003ctd\u003e65%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eJinxin Fertility SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview is the actual Jinxin Fertility SWOT analysis document you’ll receive upon purchase—professional quality with no surprises.\u003c\/p\u003e\n\u003cp\u003eThe content shown below is taken directly from the full report; buying unlocks the complete, editable version with in-depth insights and strategic implications.\u003c\/p\u003e\n\u003cp\u003eYou’re viewing a live excerpt of the real analysis file—purchase to download the full, detailed SWOT report immediately.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752133177721,"sku":"jxr-fertility-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/jxr-fertility-swot-analysis.png?v=1772238111","url":"https:\/\/growthsharematrix.com\/products\/jxr-fertility-swot-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}